<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02896842</url>
  </required_header>
  <id_info>
    <org_study_id>09/38_ Optim Imatinib</org_study_id>
    <nct_id>NCT02896842</nct_id>
  </id_info>
  <brief_title>A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CML</brief_title>
  <acronym>OPTIMIMATINIB</acronym>
  <official_title>A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate (Glivec®) Plasmatic Through Level in Patients Newly Diagnosed With Chronic Phase Chronic Myelogenous Leukaemia (CP-CML).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Versailles Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Versailles Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Imatinib mesylate (Gleevec/Glivec, IM) is currently the gold standard or CML-CP front line
      therapy. The recommended dose of IM is 400 mg/day. The rates of complete cytogenetic
      responses at 3, 6 and 12 months are 27%, 50% and 69% respectively. The optimal IM daily dose
      is not yet determined and randomized studies addressing this question are on-going. First
      results from the TOPS trial (EHA 2008 congress) suggest a more rapid kinetic of response for
      patients treated with imatinib high dose. Recent studies revealed that initial Imatinib
      plasmatic dosage is predictive for achieving complete cytogenetic responses (CCR) and that a
      dosage of 1000 ng/ml is associated with a higher proportion of major molecular responses
      (MMR) (Picard et al., Blood 2007, Larson et al. Blood 2007).

      Results from the study of Larson et al. indicate that around 40% of the patients had a trough
      plasmatic level below 1000 ng/ml after day 28 of imatinib 400 mg/d. The major molecular
      response rate at 12 months for the patients with the lower plasmatic through level is 25.4%
      compared to 40.1% for the patients with a plasmatic dosage over 800 to 1000 ng/ml.

      Investigators propose to adapt the imatinib daily dose in case of imatinib through plasmatic
      level at day 28 below 1000 ng/ml. Patients with a trough plasmatic dosage ≤ 1000 ng/ml will
      be randomized between a prospective adaptation strategy of the imatinib daily dose (cohort 1)
      versus observation only (cohort 2). The patients with adequate imatinib dosage (&gt; 1000 ng/ml)
      will be followed up according the ELN recommendation (cohort 3). Imatinib trough plasmatic
      level will then be rechecked every month thereafter for patients in cohort 1 and cohort 2 and
      every three months in cohort 3. The first endpoint of the study will be the rate of major
      molecular response at 12 months in cohort 1. Our hypothesis is to improve the 12 months MMR
      rate with the optimized strategy (cohort 1) from 25% of MMR at 12 months to 40% of MMR at 12
      months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The major molecular response rate at 12 months in cohort 1.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete cytogenetic response at 6 and 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major molecular response rate at 12 months in cohort 2 and cohort 3.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major molecular response at 3, 6, and 9 months</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete molecular response 6 and 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between plasmatic dosage and efficacy</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between plasmatic dosage and tolerance</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">139</enrollment>
  <condition>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</condition>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>cohort 3: Imatinib through dosage ≥ 1000 ng/ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohort 2 : Imatinib standard dose Imatinib through dosage &lt; 1000 ng/ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1 : dose adjustment based on trough plasmatic level value Imatinib through dosage &lt; 1000 ng/ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Posology dose modification</intervention_name>
    <arm_group_label>Experimental arm</arm_group_label>
    <other_name>Cohort 1 : dose adjustment based on trough plasmatic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>active comparator</intervention_name>
    <arm_group_label>Active comparator</arm_group_label>
    <other_name>Cohort 2 : Imatinib standard dose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patient ≥ 18 years

          2. Philadelphia chromosome positive newly diagnosed chronic myelogenous leukaemia (≤ 4
             months) in first chronic phase.

          3. Not previously treated with tyrosine kinase inhibitors other than imatinib

          4. Prior treatment with imatinib during less than 13 weeks

          5. Signed written inform consent

          6. Women of childbearing potential (WOCBP) must be using an adequate method of
             contraception

        Exclusion Criteria:

          1. Patients with BCR-ABL positive, Philadelphia negative CML

          2. Patient previously treated with TKI other than imatinib

          3. Pregnancy

          4. Active malignancy

          5. Concurrent severe diseases which exclude the administration of therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH d'Annecy</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH argenteuil</name>
      <address>
        <city>Argenteuil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Boulogne</name>
      <address>
        <city>Boulogne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU CAEN</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Dieppe</name>
      <address>
        <city>Dieppe</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Dunkerque</name>
      <address>
        <city>Dunkerque</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Versailles</name>
      <address>
        <city>Le Chesnay</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Meaux</name>
      <address>
        <city>Meaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Bon secours</name>
      <address>
        <city>Metz</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital La Source</name>
      <address>
        <city>Orléans La Source</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Purpan</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2016</study_first_submitted>
  <study_first_submitted_qc>September 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2016</study_first_posted>
  <last_update_submitted>November 21, 2017</last_update_submitted>
  <last_update_submitted_qc>November 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Versailles Hospital</investigator_affiliation>
    <investigator_full_name>Philippe ROUSSELOT</investigator_full_name>
    <investigator_title>Study coordonator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

